Overview: BRCA1 BRCA2 Drug Profiling Panel
Introduction: The BRCA1 BRCA2 Drug Profiling Panel is a diagnostic tool designed to assess BRCA mutations for drug response using whole blood samples. In India, BRCA mutations in breast/ovarian cancer patients (5-10 percent of cases) predict response to PARP inhibitors (olaparib, niraparib), approved for maintenance therapy in BRCA-positive advanced disease. High burden of breast cancer (~178,000 cases/year) and ovarian cancer (~46,000 cases/year), with underdiagnosis of BRCA status in rural/low-SES patients due to limited molecular testing, delayed targeted therapy leading to poor progression-free survival. Per molecular pathology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for mutation profiling over 1-2 days with high sensitivity/specificity, valuable for guiding PARP inhibitor eligibility. This diagnostic falls under drug response screening and targets breast/ovarian cancer patients, addressing accurate detection to optimize therapy and improve outcomes. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise treatment selection and reducing cancer mortality. Its whole blood-based approach ensures reliable detection.
Other Names: BRCA Drug Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: PARP inhibitor linkage post-BRCA discovery; in India, prominence with targeted therapy access.
Purpose: The test profiles 1 parameter (BRCA1 and BRCA2 drug profiling analysis) to guide drug response assessment, identify PARP inhibitor eligibility, inform oncology treatment.
Test Parameters: 1. BRCA1 and BRCA2 Drug Profiling Analysis.
Pretest Condition: No fasting required; patients should report breast/ovarian cancer diagnosis or family history.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on cancer type, stage, prior therapy, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated mutations including poor response, benefits of profiling, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive profiling indicates PARP inhibitor benefit, necessitating specialist input. Negative may require follow-up if clinical suspicion high.
Specialist Consultation: Medical oncologists should be consulted for management.
Additional Supporting Tests: Tumor BRCA testing for confirmation.
Test Limitations: May miss somatic mutations; comprehensive approach required.
References: Indian Journal of Medical Oncology 2024, BRCA Drug Studies India 2023.
